High Throughput Influenza Antiviral Screening Assay
Author Information
Author(s): Maryna C Eichelberger, Arash Hassantoufighi, Meng Wu, Min Li
Primary Institution: Center for Biologics Evaluation and Research, Food and Drug Administration
Hypothesis
Measuring neuraminidase activity can provide a sensitive and practical method for high throughput screening of influenza antivirals.
Conclusion
The AVINA assay effectively identifies antivirals and drug-resistant influenza strains using neuraminidase activity as a read-out.
Supporting Evidence
- The AVINA assay allows for rapid and sensitive identification of influenza inhibitors.
- Known influenza inhibitors were effectively detected using the AVINA assay.
- The assay can evaluate drug toxicity alongside antiviral activity.
Takeaway
Scientists created a new test to quickly find medicines that can stop the flu virus from making more copies of itself.
Methodology
The AVINA assay uses viral neuraminidase activity to quantify influenza replication in a high throughput format.
Limitations
The assay may not be suitable for viruses that are deficient in neuraminidase activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website